India's Caps On Cardiac Stent Pricing Angers Industry
Executive Summary
India has brought cardiac stents under price controls after an advisory body to the health ministry contended there was “huge exploitation” of patients by the medical devices industry. The move drew strong criticism from industry which said the decision “does not bode well” for Prime Minister Narendra Modi’s stepped-up drive to attract foreign investment.
You may also be interested in...
Capping Of Coronary Stent Prices In India Is ‘Deeply Disappointing,’ Says US Medtech Body
The Indian government has fixed the maximum price that can be charged for coronary stents for a year in an attempt to make treatments more affordable. US medtech companies say, however, that a singular focus on pricing is misguided and that steps should be taken to fix “inefficiencies” in the health-care ecosystem.
Device Manufacturers See ‘Irreparable’ Harm In Indian Draft Regulations
Medical device manufacturers are starting out the New Year in an unhappy frame of mind over draft Indian government proposals to regulate the sector, claiming that certain rules could cause “irreparable damages” to the industry. They’re also chafing at separate government plans to slap price controls on cardiac stents.
Could Indian heart stent study findings lead to price cuts?
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.